|
1
|
Hsieh JJ, Purdue MP, Signoretti S, Swanton
C, Albiges L, Schmidinger M, Heng DY, Larkin J and Ficarra V: Renal
cell carcinoma. Nat Rev Dis Primers. 3:170092017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ratain MJ, Eisen T, Stadler WM, Flaherty
KT, Kaye SB, Rosner GL, Gore M, Desai AA, Patnaik A, Xiong HQ, et
al: Phase II placebo-controlled randomized discontinuation trial of
sorafenib in patients with metastatic renal cell carcinoma. J Clin
Oncol. 24:2505–2512. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Escudier B, Eisen T, Stadler WM, Szczylik
C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA,
et al: Sorafenib in advanced clear-cell renal-cell carcinoma. N
Engl J Med. 356:125–134. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Naito S, Yamamoto N, Takayama T, Muramoto
M, Shinohara N, Nishiyama K, Takahashi A, Maruyama R, Saika T,
Hoshi S, et al: Prognosis of Japanese metastatic renal cell
carcinoma patients in the cytokine era: A cooperative group report
of 1463 patients. Eur Urol. 57:317–325. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Motzer RJ, Hutson TE, Tomczak P,
Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik
C, Kim ST, et al: Sunitinib versus interferon alfa in metastatic
renal-cell carcinoma. N Engl J Med. 356:115–124. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rini BI, Escudier B, Tomczak P, Kaprin A,
Szczylik C, Hutson TE, Michaelson MD, Gorbunova VA, Gore ME,
Rusakov IG, et al: Comparative effectiveness of axitinib versus
sorafenib in advanced renal cell carcinoma (AXIS): A randomised
phase 3 trial. Lancet. 378:1931–1939. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Motzer RJ, Hutson TE, Cella D, Reeves J,
Hawkins R, Guo J, Nathan P, Staehler M, de Souza P, Merchan JR, et
al: Pazopanib versus sunitinib in metastatic renal-cell carcinoma.
N Engl J Med. 369:722–731. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Motzer RJ, Escudier B, Oudard S, Hutson
TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA,
Hollaender N, et al: Efficacy of everolimus in advanced renal cell
carcinoma: A double-blind, randomised, placebo-controlled phase III
trial. Lancet. 372:449–456. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hudes G, Carducci M, Tomczak P, Dutcher J,
Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi
I, et al: Temsirolimus, interferon alfa, or both for advanced
renal-cell carcinoma. N Engl J Med. 356:2271–2281. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Motzer RJ, Escudier B, McDermott DF,
George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G,
Plimack ER, et al: Nivolumab versus everolimus in advanced
renal-cell carcinoma. N Engl J Med. 373:1803–1813. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Miyake H, Miyazaki A, Imai S, Harada K and
Fujisawa M: Early tumor shrinkage under treatment with first-line
tyrosine kinase inhibitors as a predictor of overall survival in
patients with metastatic renal cell carcinoma: A retrospective
multi-institutional study in Japan. Target Oncol. 11:175–182. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rini BI, Gruenwald V, Jonasch E, Fishman
MN, Tomita Y, Michaelson MD, Tarazi J, Cisar L, Hariharan S, Bair
AH, et al: Long-term duration of first-line axitinib treatment in
advanced renal cell carcinoma. Target Oncol. 12:333–340. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Grünwald V, Lin X, Kalanovic D and
Simantov R: Early tumour shrinkage: A tool for the detection of
early clinical activity in metastatic renal cell carcinoma. Eur
Urol. 70:1006–1015. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Heng DY, Xie W, Regan MM, Warren MA,
Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, et al:
Prognostic factors for overall survival in patients with metastatic
renal cell carcinoma treated with vascular endothelial growth
factor-targeted agents: Results from a large, multicenter study. J
Clin Oncol. 27:5794–5799. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Miyake H, Harada K, Ozono S and Fujisawa
M: Prognostic significance of early tumor shrinkage under
second-line targeted therapy for metastatic renal cell carcinoma: A
retrospective multi-institutional study in Japan. Mol Diagn Ther.
20:385–392. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ishihara H, Yagisawa T, Kondo T, Omae K,
Takagi T, Iizuka J, Kobayashi H and Tanabe K: Effect of the timing
of best tumor shrinkage on survival of patients with metastatic
renal cell carcinoma who received first-line tyrosine kinase
inhibitor therapy. Int J Clin Oncol. 22:126–135. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rixe O, Bukowski RM, Michaelson MD,
Wilding G, Hudes GR, Bolte O, Motzer RJ, Bycott P, Liau KF, Freddo
J, et al: Axitinib treatment in patients with cytokine-refractory
metastatic renal-cell cancer: A phase II study. Lancet Oncol.
8:975–984. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Karam JA, Devine CE, Urbauer DL, Lozano M,
Maity T, Ahrar K, Tamboli P, Tannir NM and Wood CG: Phase 2 trial
of neoadjuvant axitinib in patients with locally advanced
nonmetastatic clear cell renal cell carcinoma. Eur Urol.
66:874–880. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Oya M, Tomita Y, Fukasawa S, Shinohara N,
Habuchi T, Rini BI, Fujii Y, Kamei Y, Umeyama Y, Bair AH and Uemura
H: Overall survival of first-line axitinib in metastatic renal cell
carcinoma: Japanese subgroup analysis from phase II study. Cancer
Sci. 108:1231–1239. 2017. View Article : Google Scholar : PubMed/NCBI
|
